Morgan Stanley lifted its target price and gave an overweight rating for Arrowhead Pharmaceuticals, while Norges Bank acquired a new stake in the company's shares.
2 reports, 1 independent
Updated Aug 2
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley lifted its target price and gave an overweight rating for Arrowhead Pharmaceuticals, while Norges Bank acquired a new stake in the company's shares.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Arrowhead Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
-
Norges Bank
central bank of Norway
Related events
- Morgan Stanley raised its price target and maintained an overweight rating for Wingstop.
- Norges Bank acquired a new stake in Paychex while Morgan Stanley raised its target price for the company's stock.
- Morgan Stanley increased price target and rating for Omnicom Group.
- Morgan Stanley raised its price target for AT&T on July 19, 2025.
- Morgan Stanley and Manufacturers Life Insurance Company purchased a new position and reiterated an overweight rating for Monopar Therapeutics.
Coverage
Newest first; wire copies grouped- tickerreport.comInceptionr LLC Purchases New Position in Arrowhead Pharmaceuticals, Inc. $ARWR